Evidence map›Paper›PMID 36172382›Full record

ReviewFrontiers in immunology2022

Role of RGC-32 in multiple sclerosis and neuroinflammation - few answers and many questions.

Alexandru Tatomir, Jacob Cuevas, Tudor C Badea, Dafin F Muresanu, Violeta Rus, Horea Rus

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. The mechanism and potential therapeutic target of piezo channels in pain.Frontiers in pain research (Lausanne, Switzerland) · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Alexandru TatomirDepartment of Neurology, University of Maryland, School of Medicine, Baltimore, MD, United States.
Jacob CuevasDepartment of Neurology, University of Maryland, School of Medicine, Baltimore, MD, United States.
Tudor C BadeaResearch and Development Institute, Faculty of Medicine, Transylvania University of Brasov, Brasov, Romania.
Dafin F MuresanuDepartment of Neurosciences, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Violeta RusDepartment of Medicine, Division of Rheumatology and Clinical Immunology, University of Maryland, School of Medicine, Baltimore, MD, United States.
Horea RusDepartment of Neurology, University of Maryland, School of Medicine, Baltimore, MD, United States.
University of Maryland, Baltimore · USIuliu Hațieganu University of Medicine and Pharmacy · ROTransylvania University of Brașov · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent advances in understanding the pathogenesis of multiple sclerosis (MS) have brought into the spotlight the major role played by reactive astrocytes in this condition. Response Gene to Complement (RGC)-32 is a gene induced by complement activation, growth factors, and cytokines, notably transforming growth factor β, that is involved in the modulation of processes such as angiogenesis, fibrosis, cell migration, and cell differentiation. Studies have uncovered the crucial role that RGC-32 plays in promoting the differentiation of Th17 cells, a subtype of CD4

Indexed as

Cell Cycle ProteinsMultiple SclerosisMuscle ProteinsNerve Tissue ProteinsAnimalsBiomarkersComplement System ProteinsCytokinesHumansMiceNeuroinflammatory DiseasesNuclear ProteinsTransforming Growth Factor betaBiomarkersCell Cycle ProteinsComplement System ProteinsCytokinesMuscle ProteinsNerve Tissue ProteinsNuclear ProteinsRgc-32 protein, mouseRGCC protein, humanTransforming Growth Factor betaastrocyteEAE (experimental autoimmune encephalomyelitis)multiple sclerosisneuroinflammationradial gliaRGC-32Th17

Identifiers

PMID36172382
PMCPMC9510783
OpenAlexW4297872388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.